The next big obesity medication coming down the pipeline will likely come in pill form. Eli Lilly has just released the latest positive Phase III trial results of its experimental oral GLP-1 drug, orforglipron. On Tuesday morning, Eli Lilly reported that orforglipron met the benchmarks of the company’s Phase III ATTAIN-2 study. People taking orforglipron […]